# Jiuwei Cui

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jiuwei-cui/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,606 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 269 |
| Last Known Institution | Jilin University |
| OpenAlex ID | https://openalex.org/A5036233749 |
| ORCID iD | https://orcid.org/0000-0001-6496-7550 |
| Works | 621 |

## Researcher papers

- [Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study](https://scholariq.org/papers/sintilimab-plus-a-bevacizumab-biosimilar-ibi305-versus-sorafenib-in-unresectable/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)](https://scholariq.org/papers/sintilimab-plus-platinum-and-gemcitabine-as-first-line-treatment-for-advanced-or/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-or/)
- [Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-bevacizumab-biosimilar-ibi305-and-chemotherapy-for-patients-with/)
- [Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study](https://scholariq.org/papers/furmonertinib-ast2818-versus-gefitinib-as-first-line-therapy-for-chinese/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-patients-with-egfr-mutated-non-squamous-non/)
- [Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)](https://scholariq.org/papers/toripalimab-plus-chemotherapy-for-patients-with-treatment-naive-advanced-non/)
- [A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies](https://scholariq.org/papers/a-novel-antisense-long-noncoding-rna-within-the-igf1r-gene-locus-is-imprinted-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Nutrition and Health in Aging](https://scholariq.org/topics/nutrition-and-health-in-aging/)

## Researcher university

- [Jilin University](https://scholariq.org/institutions/jilin-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.